Migraine Treatment Optimization Questionnaire-4 (mTOQ-4)

Why use it

Migraine affects 12–15% of the general population and is a leading cause of disability worldwide. Despite the availability of effective treatments (triptans, gepants, ditans), many patients receive suboptimal acute therapy or never have their treatment adequately reviewed. The mTOQ-4 provides a brief, validated, structured method for identifying treatment-inadequate patients in primary care and neurology settings, prompting timely therapeutic adjustments and reducing migraine-related disability.

About

The Migraine Treatment Optimization Questionnaire-4 (mTOQ-4) is a validated 4-item patient-reported outcome measure developed by Lipton and colleagues to assess whether a patient's current acute migraine treatment is meeting clinical treatment goals. The mTOQ-4 evaluates four key dimensions of migraine treatment response: (1) pain freedom within 2 hours; (2) ability to function normally within 2 hours; (3) consistency of response across attacks; and (4) absence of headache recurrence within 24 hours. Each question is answered as "always/almost always" (score 2), "sometimes/about half the time" (score 1), or "rarely/never" (score 0). Total scores range from 0 to 8. A score ≥5 indicates an optimized treatment response. Scores <5 suggest suboptimal treatment and should prompt consideration of acute medication change, dose optimization, or preventive therapy initiation. The mTOQ-4 has been validated in randomized controlled trials of triptan therapy and is endorsed in headache treatment guidelines as a tool for treatment monitoring.

When to use

• At any scheduled visit for a patient with known migraine using acute medication
• When a patient reports incomplete or inconsistent response to current acute therapy
• Before initiating preventive migraine therapy — assess acute treatment optimization first
• Following a change in acute medication to assess whether new therapy is adequate
• Annual migraine management review in primary care or neurology settings
• Assessing whether triptans, gepants, or ditans are achieving IHS-recommended treatment goals

Formula

Pearls & pitfalls

• Treatment should be taken at mild pain intensity (not waiting for severe headache) — early intervention dramatically improves 2-hour pain freedom rates for all acute migraine drugs.
• Triptans are most effective when taken within 1 hour of headache onset and before central sensitization develops (allodynia is a clinical marker of central sensitization).
• Medication overuse headache (MOH) — using acute medications on ≥10 days/month for triptans/ergots or ≥15 days/month for analgesics/NSAIDs — can paradoxically worsen migraine frequency. The mTOQ-4 does not screen for MOH specifically, but high treatment use is a red flag.
• CGRP-targeting acute treatments (gepants: rimegepant, ubrogepant; ditans: lasmiditan) are effective alternatives for patients who fail triptans or have cardiovascular contraindications to triptans.
• The 2-hour pain freedom rate is the current gold standard endpoint for acute migraine trials (replacing "2-hour headache response" which only required reduction from severe to mild).
• Headache recurrence (return of headache within 24 hours after initial response) is particularly problematic with short-acting triptans (sumatriptan) — longer-acting triptans (frovatriptan, naratriptan) have lower recurrence rates.
• The mTOQ-4 evaluates consistency across attacks — even highly effective drugs may not work every time; a response rate of >50% of attacks is generally considered adequate.
• Patients with nausea/vomiting at headache onset benefit from non-oral formulations: nasal spray (sumatriptan, zolmitriptan), subcutaneous injection (sumatriptan), or rapidly dissolving oral formulations.

Next steps

mTOQ-4 ≥5 (Optimized): Current acute treatment is effective. Continue current regimen. Reinforce early treatment approach (treat at mild pain, not moderate/severe). mTOQ-4 <5 (Suboptimal): Assess barriers to treatment: Is the patient taking medication early enough? Correct dose? Non-oral formulation needed (nasal spray, subcutaneous for vomiting)? Consider: changing to a different triptan (significant inter-patient variability), adding an antiemetic, switching to a gepant (rimegepant, ubrogepant) or ditan (lasmiditan), or optimizing NSAID combination. If ≥4 migraine days/month with functional impairment: consider preventive therapy (topiramate, valproate, amitriptyline, beta-blockers, CGRP monoclonal antibodies).

Evidence

Lipton RB et al. Migraine Treatment Optimization Questionnaire: a patient self-assessment tool to identify treatment opportunities. Headache. 2009;49(8):1124-1136. PMID:19531390. Validated in clinical trial setting with triptans. mTOQ-4 threshold of ≥5 identified optimized treatment response with sensitivity 0.77, specificity 0.71. Endorsed by IHS and EHF treatment optimization frameworks.

References

1. Lipton RB et al. Migraine Treatment Optimization Questionnaire: a patient self-assessment tool to identify treatment opportunities. Headache. 2009;49(8):1124-1136. — link
2. Diener HC et al. European principles of managing common headache disorders in primary care. J Headache Pain. 2007;8 Suppl 1:S3-S47. — link
3. Goadsby PJ et al. Diagnosis and management of migraine. BMJ. 2017;358:j3221. — link